Written and maintained by CASRAI Editorial Board
Last updated
Biofourmis is a digital therapeutics and virtual care platform that combines wearable continuous biosensors, FDA 510(k)-cleared physiological analytics (the Biovitals Analytics Engine), and clinical care command software to support Acute Hospital Care at Home programs, post-acute remote patient monitoring (RPM), and decentralized clinical trials (DCTs). When health systems and clinical research sponsors evaluate enterprise remote care platforms, they frequently compare Biofourmis against Current Health (part of Best Buy Health) and Vivify Health (part of Optum) to match continuous vs. episodic physiological capture, nursing command center workflows, and electronic health record (EHR) integration depth to their clinical protocols.
What Is Biofourmis and How Does the Biovitals Analytics Engine Work?
Unlike basic cellular RPM kits that only forward discrete spot-check readings, Biofourmis centers its platform on multivariate physiological modeling and clinical decision support:
- FDA 510(k)-Cleared Biovitals Analytics Engine (
K183282): Cleared as a Class II software platform for ambulatory physiological monitoring, the Biovitals Analytics Engine ingests continuous streams of heart rate, respiratory rate, skin temperature, pulse oximetry, and physical activity from medical-grade wearable sensors. Rather than relying solely on static population-wide threshold alarms, it establishes a personalized baseline for each patient and computes a dynamic composite deviation score—the Biovitals Index—to alert clinical teams to early physiological decompensation in conditions such as heart failure, chronic obstructive pulmonary disease (COPD), and oncology therapy toxicity. - Biofourmis Care (Virtual Care & Hospital at Home): Provides a clinician command dashboard, configurable care pathways, symptom questionnaires, video visit capabilities, and bi-directional EHR integration via HL7 v2 and SMART on FHIR. It is widely deployed under the Centers for Medicare & Medicaid Services (CMS) Acute Hospital Care at Home waiver to monitor inpatient-acuity patients in their homes.
- Biofourmis Act (Decentralized Clinical Trials): Enables biopharma sponsors and contract research organizations (CROs) to collect continuous digital biomarkers, electronic patient-reported outcomes (ePRO), and medication adherence data for Phase I–IV clinical trials, including early detection of cytokine release syndrome (CRS) in immunooncology protocols.
How Is Biofourmis Used in Clinical Research and Healthcare?
Health systems and trial sponsors deploy enterprise virtual care platforms across three distinct clinical workflows, where Biofourmis, Current Health, and Vivify Health offer specialized architectural strengths:
- Acute Hospital Care at Home (Inpatient Acuity): CMS waiver programs require twice-daily in-person or paramedic/nursing visits combined with continuous or high-frequency physiological monitoring and immediate 24/7 clinical escalation. Both Biofourmis and Current Health specialize in continuous wearable physiological streaming and supply-chain logistics for inpatient-level home care, bridging acute telemetry and telehealth nursing command centers.
- Chronic Disease Management & Post-Discharge RPM: Health systems managing 30-day hospital readmission risk for heart failure, hypertension, and diabetes often prioritize broad peripheral kit compatibility, automated patient coaching, and population health stratification. Vivify Health (Optum) is heavily established in large-scale chronic care management and payer-provider population health programs, using tablet- or bring-your-own-device (BYOD) pathways paired with Bluetooth peripheral kits and cellular RPM devices.
- Biopharma Digital Biomarker & DCT Endpoints: Sponsors running oncology, cardiology, or immunology trials require 21 CFR Part 11 audit trails, validated wearable algorithms, and raw waveform or epoch export into electronic data capture (EDC) systems. Here, Biofourmis’s FDA-cleared Biovitals algorithms differentiate it from purely operational RPM dashboards that act only as Medical Device Data Systems (MDDS).
Comparison: Biofourmis vs. Current Health vs. Vivify Health
The table below compares Biofourmis, Current Health, and Vivify Health across regulatory clearance, biosensor architecture, primary clinical care setting, and trial readiness:
| Evaluation Dimension | Biofourmis (Biovitals / Care / Act) | Current Health (Best Buy Health) | Vivify Health (Optum) |
|---|---|---|---|
| Primary Care Settings | Acute Hospital Care at Home, post-acute specialty RPM, and biopharma decentralized clinical trials | Acute Hospital Care at Home, oncology toxicity monitoring, and high-acuity transitional care | Population-scale chronic disease RPM, post-discharge readmission reduction, and payer care management |
| FDA 510(k) Regulatory Footprint | FDA 510(k)-cleared Biovitals Analytics Engine (K183282) for multivariate ambulatory physiological analytics |
FDA 510(k)-cleared Gen 2 continuous wearable monitoring system (K191272 / K210133) for home and hospital use |
Software platform operates primarily as a care management and MDDS aggregation hub paired with 510(k)-cleared third-party peripherals |
| Sensor & Hardware Model | Device-agnostic ecosystem supporting continuous upper-arm/chest biosensors plus Bluetooth spot-check peripherals | Proprietary upper-arm continuous wearable (pulse rate, SpO2, respiration, skin temperature, mobility) plus peripheral hub | Managed tablet kits and BYOD mobile app paired with Bluetooth blood pressure cuffs, scales, pulse oximeters, and glucometers |
| Clinical Alerting Logic | Personalized multivariate baseline modeling (Biovitals Index) plus configurable clinical pathway rules | Configurable multi-vital physiological deterioration alarms combining continuous trend duration and vital thresholds | Rule-based clinical pathways, biometric threshold alerts, and branching health-literacy symptom surveys |
| Logistics & Home Kitting | End-to-end device sanitization, kitting, direct-to-patient shipping, and retrieval services | Integrated with Best Buy Health / Geek Squad logistics for rapid home delivery, setup, and hardware recovery | Turnkey kit fulfillment, cellular tablet provisioning, and refurbishing logistics for large health plans and IDNs |
Selection Checklist for Health Systems and Trial Sponsors
- Choose Biofourmis when your protocol requires FDA-cleared multivariate physiological deviation scoring (Biovitals Index), Guideline-Directed Medical Therapy (GDMT) titration support in heart failure, or a unified platform spanning both health system Hospital at Home and biopharma clinical trials.
- Choose Current Health when your health system wants a dedicated FDA-cleared upper-arm wearable purpose-built for continuous inpatient-at-home vital sign streaming, integrated peripheral connectivity (including home connectivity hubs for patients without broadband), and nationwide Best Buy Health logistics support.
- Choose Vivify Health when scaling chronic care management and post-acute readmission prevention across tens of thousands of patients in an integrated delivery network (IDN) or payer-led care management program using episodic Bluetooth vital sign kits and interactive patient education pathways.
Frequently Asked Questions
What is biofourmis?
Biofourmis is a virtual care and digital therapeutics technology company whose platform combines medical-grade wearable biosensors with the FDA 510(k)-cleared Biovitals Analytics Engine (K183282) to detect early physiological deterioration, support Acute Hospital Care at Home programs, and capture continuous digital endpoints in clinical trials.
How is biofourmis used in clinical research and healthcare?
In healthcare delivery, clinicians use Biofourmis Care to remotely monitor inpatient-acuity Hospital at Home patients and post-acute heart failure or oncology patients via continuous wearable telemetry and EHR-integrated dashboards. In clinical research, biopharma sponsors use Biofourmis Act to collect continuous physiological biomarkers, ePROs, and safety monitoring signals (such as early fever or tachycardia trends in immunotherapy trials) across decentralized trial cohorts.
